Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind randomized placebo-controlled crossover multiple-dose study of LJN452 in bile acid diarrhea
2015-003192-30Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in primary bile acid diarrhea (PBAD) and intestinal malabsorption comparing LJN452 sequence arm with Placebo sequence arm (2 arms). Primary endpoint: Safety and tolerability. Started Dec 2015; status: completed.
02
Drugs
tropifexor
03
Conditions
primary bile acid diarrhea (PBAD)intestinal malabsorption
Beyond the preview
Go deeper on 2015-003192-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003192-30.